Insulin resistance as a predictor of cardiovascular disease in patients on peritoneal dialysis

Peritoneal Dialysis International

Volumn 33, Issue 4, 2013, Pages 411-418

  Li, Yun ^a   Zhang, Lihua ^a   Gu, Yong ^a   Hao, Chuanming ^a   Zhu, Tongying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cardiovascular morbidity; Cardiovascular mortality; Chronic kidney disease; Homeostatic model assessment; Insulin resistance

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SURVIVAL;

CARDIOVASCULAR MORBIDITY; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; HOMEOSTATIC MODEL ASSESSMENT; INSULIN RESISTANCE;

AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INSULIN RESISTANCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84880047551     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2012.00037     Document Type: Article

References (37)

1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-94.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-28.
4. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl JMed 1996; 334:952-7.
5. Fortes PC, de Moraes TP, Mendes JG, Stinghen AE, Ribeiro SC, Pecoits-Filho R. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int 2009; 29(Suppl 2):S145-8.
6. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. Am Soc Nephrol 2002; 13:1894-900.
7. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Am Soc Nephrol 2005; 16:529-38.
8. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003; (84):S117-20.
9. Tatar E, Demirci MS, Kircelli F, Gungor O, Turan MN, Sevinc Ok E, et al. Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients. Int Urol Nephrol 2012; 44:255-62.
10. Sevinc Ok E, Asci G, Kircelli F, Duman S, Dheir H, Sezis Demirci M, et al. Relationship between glucose exposure via peritoneal dialysis solutions and coronary artery calcification in non-diabetic peritoneal dialysis patients. Int Urol Nephrol 2012; 44:1847-53
11. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293:1737-45.
12. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. Am Soc Nephrol 2007; 18:304-11.
13. Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. Nephrol 2008; 21:635-44.
14. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560-7.
15. Hakim RM, Lowrie E. Obesity and mortality in ESRD: is it good to be fat? Kidney Int 1999; 55:1580-1.
16. Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. Am Soc Nephrol 2008; 19:1059-62.
17. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61:1887-93.
18. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22:818-22.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-19.
20. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143:174-83.
21. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin Am Soc Nephrol 2009; 4:1620-8.
22. DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. Clin Invest 1978; 62:425-35.
23. Glanton CW, Hypolite IO, Hshieh PB, Agodoa LY, Yuan CM, Abbott KC. Factors associated with improved short term survival in obese end stage renal disease patients. Ann Epidemiol 2003; 13:136-43.
24. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am Clin Nutr 2004; 80:324-32.
25. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am JClin Nutr 2004; 80:1222-9.
26. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. Am Soc Nephrol 2003; 14:2366-72.
27. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Perez Castrillon JL, et al. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diabetes Res Clin Pract 2009; 84:174-8.
28. de Luis DA, Sagrado MG, Conde R, Aller R, Izaola O, de la Fuente B, et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naive diabetes obese patients. Diabetes Res Clin Pract 2010; 89:110-14.
29. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. Atheroscler Thromb 2011; 18:108-14.
30. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 2008; 196:398-404.
31. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. Clin Invest 1993; 92:141-6.
32. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42:945-9.
33. Tamura T, Johnston KE, Bergman SM. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. Am Soc Nephrol 1996; 7:2414-18.
34. Cioni A, Sordini C, Cavallini I, Bigazzi R, Campese VM. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Perit Dial Int 2010; 30:66-71.
35. Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21:494-8.
36. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 2001; 89:348-9.
37. Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 2007; 22:2554-62.